M. Sherry Ku, PhD（顧曼芹博士）
Chairmen & Chief Executive Officer
Savior Lifetec Corp. (SLC)
Dr. Sherry Ku is currently the Chairperson of Board and CEO of Savior Lifetec Corp. (2015 IPO in Taiwan). Previously she was the founding President and Board Member of RuenHuei Biopharmaceutical Company, and the founding President/CSO of TWi Biotech/TWi Pharma (Anchen Taiwan, 2012 IPO). Under her leadership, 6 High Barrier Abbreviated New Drug Applications (ANDAs), including 3 Paragraph IV, were filed within 18 months. Before her returning to Taiwan, Dr. Ku headed up the Pharmaceutical Development group in Wyeth Research USA (now Pfizer). Her responsibilities starts from discovery interface through clinical proof of concept. She oversees new drug development for over 170 new clinical leads, resulting in 85 original filings of New Molecular Entity (NME) Investigational New Drug (IND) and 8 commercial products including Suprax, Zosyn/Tazocin, Zebeta, Isovorin, Thioplex, Sonata, Tygacil and Bosutinib from pre-formulation through New Drug Application (NDA) and FDA’s pre-approval inspection (PAI) activities. Dr. Ku is a registered pharmacist and has a PhD degree in Pharmaceutics and Pharmaceutical Chemistry. She currently holds over 70 patents/invention disclosures and has 62 journal publications. She was the Vice Chair of NJ Pharmaceutical Discussion Group and is the chair elect of AAPS Physical Pharmacy and Biopharmaceutical section. She sits on USP expert council and consults for CFDA, TFDA, IPEC and various Quality Councils.